Geneva Partners LLC Has $8.40 Million Stake in Eli Lilly and Company (NYSE:LLY)

Geneva Partners LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 12.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,279 shares of the company’s stock after buying an additional 1,021 shares during the period. Eli Lilly and Company accounts for 3.5% of Geneva Partners LLC’s investment portfolio, making the stock its 9th biggest position. Geneva Partners LLC’s holdings in Eli Lilly and Company were worth $8,401,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Independent Advisor Alliance lifted its stake in Eli Lilly and Company by 1.7% in the 4th quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after purchasing an additional 544 shares in the last quarter. Apexium Financial LP lifted its stake in Eli Lilly and Company by 1,819.1% in the 4th quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after purchasing an additional 10,842 shares in the last quarter. Terril Brothers Inc. lifted its stake in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after purchasing an additional 429 shares in the last quarter. Capital Planning LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth approximately $262,000. Finally, Hartline Investment Corp lifted its stake in Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after purchasing an additional 248 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 1,214,704 shares of company stock valued at $1,066,841,316 in the last quarter. Insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on LLY. Guggenheim increased their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $956.88.

Eli Lilly and Company Trading Up 0.2 %

Eli Lilly and Company stock traded up $2.00 during trading hours on Wednesday, reaching $951.97. The stock had a trading volume of 2,496,047 shares, compared to its average volume of 3,101,510. The stock has a market cap of $904.76 billion, a PE ratio of 139.10, a PEG ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $967.00. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a fifty day simple moving average of $881.72 and a 200-day simple moving average of $810.11.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.